These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 12217742)
1. Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. Heddens D; Alberts DS; Hannigan EV; Williams SD; Garcia D; Roe DJ; Bell J; Alvarez RD Gynecol Oncol; 2002 Sep; 86(3):239-43. PubMed ID: 12217742 [TBL] [Abstract][Full Text] [Related]
2. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Hensley ML; Lebeau D; Leon LF; Venkatraman E; Waltzman R; Sabbatini P; Almadrones L; Chi D; Spriggs D Gynecol Oncol; 2001 Jun; 81(3):485-9. PubMed ID: 11371143 [TBL] [Abstract][Full Text] [Related]
3. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Dangsuwan P; Manchana T Gynecol Oncol; 2010 Mar; 116(3):522-5. PubMed ID: 20051288 [TBL] [Abstract][Full Text] [Related]
4. Carboplatin versus cisplatin in ovarian cancer. Alberts DS Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869 [TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Fujiwara K; Markman M; Morgan M; Coleman RL Gynecol Oncol; 2005 Apr; 97(1):10-5. PubMed ID: 15790431 [TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Nowrousian MR Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333 [TBL] [Abstract][Full Text] [Related]
7. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336 [TBL] [Abstract][Full Text] [Related]
8. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Markman M; Federico M; Liu PY; Hannigan E; Alberts D Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148 [TBL] [Abstract][Full Text] [Related]
9. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study. Aerts JG; Swieboda-Sadlej A; Karanikiotis C; Labourey JL; Galid A; Wheeler T; Pujol B; Van Belle S Curr Med Res Opin; 2012 Jul; 28(7):1089-99. PubMed ID: 22642866 [TBL] [Abstract][Full Text] [Related]
10. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Welch RS; James RD; Wilkinson PM; Belli F; Cowan RA Cancer J Sci Am; 1995; 1(4):261-6. PubMed ID: 9166486 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Thigpen T; Vance R; Puneky L; Khansur T Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816 [TBL] [Abstract][Full Text] [Related]
12. [Frequency of blood transfusions for anemia caused by chemotherapy in ovarian cancer patients. Thoughts about the guidelines modified in 2006 for the treatment of anemic cancer patients by the European Organisation for Research and Treatment of Cancer]. Lehoczky O; Pulay T Orv Hetil; 2007 Nov; 148(45):2133-7. PubMed ID: 17984024 [TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Oberhoff C; Neri B; Amadori D; Petry KU; Gamucci T; Rebmann U; Nowrousian MR; Voigtmann R; Monfardini S; Armand JP; Herrmann R; Netter-Pinon J; Tubiana-Mathieu N; Zwierzina H Ann Oncol; 1998 Mar; 9(3):255-60. PubMed ID: 9602258 [TBL] [Abstract][Full Text] [Related]
14. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297 [TBL] [Abstract][Full Text] [Related]
15. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Athibovonsuk P; Manchana T; Sirisabya N Gynecol Oncol; 2013 Dec; 131(3):679-82. PubMed ID: 24099839 [TBL] [Abstract][Full Text] [Related]
16. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Thatcher N; De Campos ES; Bell DR; Steward WP; Varghese G; Morant R; Vansteenkiste JF; Rosso R; Ewers SB; Sundal E; Schatzmann E; Stocker H Br J Cancer; 1999 May; 80(3-4):396-402. PubMed ID: 10408844 [TBL] [Abstract][Full Text] [Related]
17. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Dunphy FR; Dunleavy TL; Harrison BR; Boyd JH; Varvares MA; Dunphy CH; Rodriguez JJ; McDonough EM; Minster JR; McGrady MD Cancer; 1997 Apr; 79(8):1623-8. PubMed ID: 9118049 [TBL] [Abstract][Full Text] [Related]
18. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy. Malik IA; Khan ZK; Hakimali A; Sabih M; Rehman G J Pak Med Assoc; 1998 May; 48(5):127-31. PubMed ID: 9813972 [TBL] [Abstract][Full Text] [Related]
19. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895 [TBL] [Abstract][Full Text] [Related]